Characteristics of Patients With Psoriasis Treated With Various Biologics – A Danish Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Characteristics of Patients With Psoriasis Treated With Various Biologics – A Danish Cohort Study. / Schwarz, Christopher Willy; Skov, Lone; Egeberg, Alexander; Passey, Alun; Lee, Jennifer; Gorecki, Patricia; Loft, Nikolai.

In: Journal of Psoriasis and Psoriatic Arthritis, Vol. 9, No. 2, 2024, p. 51-60.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Schwarz, CW, Skov, L, Egeberg, A, Passey, A, Lee, J, Gorecki, P & Loft, N 2024, 'Characteristics of Patients With Psoriasis Treated With Various Biologics – A Danish Cohort Study', Journal of Psoriasis and Psoriatic Arthritis, vol. 9, no. 2, pp. 51-60. https://doi.org/10.1177/24755303241234292

APA

Schwarz, C. W., Skov, L., Egeberg, A., Passey, A., Lee, J., Gorecki, P., & Loft, N. (2024). Characteristics of Patients With Psoriasis Treated With Various Biologics – A Danish Cohort Study. Journal of Psoriasis and Psoriatic Arthritis, 9(2), 51-60. https://doi.org/10.1177/24755303241234292

Vancouver

Schwarz CW, Skov L, Egeberg A, Passey A, Lee J, Gorecki P et al. Characteristics of Patients With Psoriasis Treated With Various Biologics – A Danish Cohort Study. Journal of Psoriasis and Psoriatic Arthritis. 2024;9(2):51-60. https://doi.org/10.1177/24755303241234292

Author

Schwarz, Christopher Willy ; Skov, Lone ; Egeberg, Alexander ; Passey, Alun ; Lee, Jennifer ; Gorecki, Patricia ; Loft, Nikolai. / Characteristics of Patients With Psoriasis Treated With Various Biologics – A Danish Cohort Study. In: Journal of Psoriasis and Psoriatic Arthritis. 2024 ; Vol. 9, No. 2. pp. 51-60.

Bibtex

@article{bba6b77336c24e37be48c1f6627c74e8,
title = "Characteristics of Patients With Psoriasis Treated With Various Biologics – A Danish Cohort Study",
abstract = "Background: Psoriasis is associated with several comorbidities and patients with psoriasis are more often obese than individuals without psoriasis. The excess disease burden is important to consider in choice of and response to treatment at the individual level. Objective: To investigate whether patient characteristics differ across biologics for patients initiating biologic therapy and for patients still on biologic therapy after 1 year. Also, to quantify and compare the use of topical therapy among patients still on biologic therapy after 1 year. Methods: This nationwide cohort study compared characteristics of patients prescribed adalimumab, etanercept, infliximab, secukinumab or ustekinumab for treatment of psoriasis by using data from the Danish registries. Results: In the ustekinumab group, patients were younger and fewer had psoriatic arthritis. Patients treated with secukinumab and ustekinumab were less frequently co-treated with conventional systemics and topical therapy. All other patient characteristics such as sex, smoking and comorbidities other than psoriatic arthritis were similar across the biologic cohorts. Conclusion: These results highlight the need to better understand which factors to consider when prescribing biologics to patients with psoriasis.",
keywords = "biological products, comorbidity, epidemiology, psoriasis, registries",
author = "Schwarz, {Christopher Willy} and Lone Skov and Alexander Egeberg and Alun Passey and Jennifer Lee and Patricia Gorecki and Nikolai Loft",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",
year = "2024",
doi = "10.1177/24755303241234292",
language = "English",
volume = "9",
pages = "51--60",
journal = "Journal of Psoriasis and Psoriatic Arthritis",
issn = "2475-5303",
publisher = "SAGE Publications",
number = "2",

}

RIS

TY - JOUR

T1 - Characteristics of Patients With Psoriasis Treated With Various Biologics – A Danish Cohort Study

AU - Schwarz, Christopher Willy

AU - Skov, Lone

AU - Egeberg, Alexander

AU - Passey, Alun

AU - Lee, Jennifer

AU - Gorecki, Patricia

AU - Loft, Nikolai

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2024

Y1 - 2024

N2 - Background: Psoriasis is associated with several comorbidities and patients with psoriasis are more often obese than individuals without psoriasis. The excess disease burden is important to consider in choice of and response to treatment at the individual level. Objective: To investigate whether patient characteristics differ across biologics for patients initiating biologic therapy and for patients still on biologic therapy after 1 year. Also, to quantify and compare the use of topical therapy among patients still on biologic therapy after 1 year. Methods: This nationwide cohort study compared characteristics of patients prescribed adalimumab, etanercept, infliximab, secukinumab or ustekinumab for treatment of psoriasis by using data from the Danish registries. Results: In the ustekinumab group, patients were younger and fewer had psoriatic arthritis. Patients treated with secukinumab and ustekinumab were less frequently co-treated with conventional systemics and topical therapy. All other patient characteristics such as sex, smoking and comorbidities other than psoriatic arthritis were similar across the biologic cohorts. Conclusion: These results highlight the need to better understand which factors to consider when prescribing biologics to patients with psoriasis.

AB - Background: Psoriasis is associated with several comorbidities and patients with psoriasis are more often obese than individuals without psoriasis. The excess disease burden is important to consider in choice of and response to treatment at the individual level. Objective: To investigate whether patient characteristics differ across biologics for patients initiating biologic therapy and for patients still on biologic therapy after 1 year. Also, to quantify and compare the use of topical therapy among patients still on biologic therapy after 1 year. Methods: This nationwide cohort study compared characteristics of patients prescribed adalimumab, etanercept, infliximab, secukinumab or ustekinumab for treatment of psoriasis by using data from the Danish registries. Results: In the ustekinumab group, patients were younger and fewer had psoriatic arthritis. Patients treated with secukinumab and ustekinumab were less frequently co-treated with conventional systemics and topical therapy. All other patient characteristics such as sex, smoking and comorbidities other than psoriatic arthritis were similar across the biologic cohorts. Conclusion: These results highlight the need to better understand which factors to consider when prescribing biologics to patients with psoriasis.

KW - biological products

KW - comorbidity

KW - epidemiology

KW - psoriasis

KW - registries

U2 - 10.1177/24755303241234292

DO - 10.1177/24755303241234292

M3 - Journal article

AN - SCOPUS:85186183984

VL - 9

SP - 51

EP - 60

JO - Journal of Psoriasis and Psoriatic Arthritis

JF - Journal of Psoriasis and Psoriatic Arthritis

SN - 2475-5303

IS - 2

ER -

ID: 385217945